Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Aldeyra Therapeutics ( (ALDX) ) has provided an update.
On December 15, 2025, Aldeyra Therapeutics announced that the FDA has extended the PDUFA date for its investigational drug, reproxalap, intended for dry eye disease treatment, to March 16, 2026. This extension follows a request from the FDA for additional data from a clinical study report, which was submitted as a major amendment. The extension may impact Aldeyra’s regulatory timeline and market entry for reproxalap, potentially affecting stakeholders and the company’s positioning in the biotechnology sector.
The most recent analyst rating on (ALDX) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Aldeyra Therapeutics stock, see the ALDX Stock Forecast page.
Spark’s Take on ALDX Stock
According to Spark, TipRanks’ AI Analyst, ALDX is a Underperform.
Aldeyra Therapeutics faces substantial financial and regulatory challenges, reflected in its low overall score. The lack of revenue and continuous losses are significant risks, compounded by negative technical indicators. The recent FDA response letter adds further uncertainty. However, strong cash reserves and a strategic board appointment provide some potential for recovery if product development succeeds.
To see Spark’s full report on ALDX stock, click here.
More about Aldeyra Therapeutics
Aldeyra Therapeutics is a biotechnology company focused on developing innovative therapies for immune-mediated diseases. The company aims to optimize multiple pathways while minimizing toxicity through pharmaceuticals that modulate protein systems. Its product candidates include RASP modulators for systemic and retinal immune-mediated diseases, with late-stage candidates like reproxalap for dry eye disease and allergic conjunctivitis, and ADX-2191 for primary vitreoretinal lymphoma and retinitis pigmentosa.
Average Trading Volume: 807,941
Technical Sentiment Signal: Sell
Current Market Cap: $273.1M
Find detailed analytics on ALDX stock on TipRanks’ Stock Analysis page.